Enfortumab vedotin is an anti-Nectin-4 IgG1 kappa monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E via a protease-cleavable maleimidocaproyl valine-citrulline linker.
Enfortumab vedotin-ejfv is biosimilar
- TRADE NAME: Padcev (Astellas)
- INDICATIONS:
Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
Approved under accelerated approval based on tumor response rate. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.
- CLASS: Antibody-drug conjugate (ADC), Biologic, Microtubule inhibitor, Monoclonal antibody
- HALF-LIFE: 3.4 days (monoclonal antibody moiety); 2.4 days (monomethyl auristatin E moiety)
- FDA APPROVAL DATE: 12/18/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A4 inhibitors
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 06/23/2026
